NASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis $80.39 -0.45 (-0.56%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$79.43▼$82.0050-Day Range$65.00▼$80.8452-Week Range$45.50▼$84.89Volume625,486 shsAverage Volume1.02 million shsMarket Capitalization$8.49 billionP/E RatioN/ADividend YieldN/APrice Target$94.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Intra-Cellular Therapies alerts: Email Address Intra-Cellular Therapies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside18.0% Upside$94.83 Price TargetShort InterestHealthy2.77% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.97Based on 12 Articles This WeekInsider TradingSelling Shares$1.86 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.53) to $0.88 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.68 out of 5 starsMedical Sector68th out of 936 stocksPharmaceutical Preparations Industry23rd out of 436 stocks 3.4 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intra-Cellular Therapies' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.77% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intra-Cellular Therapies has recently decreased by 29.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 3.3 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Intra-Cellular Therapies this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for ITCI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,855,393.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intra-Cellular Therapies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.53) to $0.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -69.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -69.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 13.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Intra-Cellular Therapies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Intra-Cellular Therapies Stock (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesJune 26, 2024 | insidertrades.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Director Rory B. Riggs Sells 4,462 SharesJuly 26 at 3:32 AM | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $94.83 Consensus PT from AnalystsJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 24 at 8:00 AM | globenewswire.comIntra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and WebcastJuly 22, 2024 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $100.00July 21, 2024 | finance.yahoo.comAnalysts Expect Breakeven For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Before LongJuly 19, 2024 | finance.yahoo.comIntra-Cellular Therapies Inc (23I.SG)June 19, 2024 | seekingalpha.comIntra-Cellular Brightens MDD Outlook With Caplyta SuccessJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 18, 2024 | gurufocus.comWhat's Driving Intra-Cellular Therapies Inc's Surprising 15% Stock Rally?June 18, 2024 | benzinga.comIntra-Cellular Therapies' Highlights Successful Data From Second Depression StudyJune 18, 2024 | globenewswire.comIntra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive DisorderJune 10, 2024 | globenewswire.comIntra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceMay 30, 2024 | investorplace.comThe Secret Stock Stash: 3 Overlooked Picks That Belong in Every PortfolioMay 29, 2024 | ca.finance.yahoo.comITCI Aug 2024 65.000 putMay 29, 2024 | globenewswire.comIntra-Cellular Therapies to Present at the Jefferies Global Healthcare ConferenceMay 23, 2024 | globenewswire.comIntra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual MeetingMay 10, 2024 | markets.businessinsider.comMaintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study OutlookSee More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$94.83 High Stock Price Target$120.00 Low Stock Price Target$77.00 Potential Upside/Downside+18.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,670,000.00 Net Margins-21.57% Pretax Margin-21.38% Return on Equity-18.49% Return on Assets-15.26% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio5.00 Sales & Book Value Annual Sales$464.37 million Price / Sales18.28 Cash FlowN/A Price / Cash FlowN/A Book Value$6.15 per share Price / Book13.07Miscellaneous Outstanding Shares105,570,000Free Float101,985,000Market Cap$8.49 billion OptionableOptionable Beta1.01 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Sharon Mates Ph.D. (Age 71)Co-Founder, Chairman & CEO Comp: $2.23MMr. Michael I. Halstead J.D. (Age 51)President Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Comp: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Comp: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsViela BioNASDAQ:VIERa PharmaceuticalsNASDAQ:RARXAimmune TherapeuticsNASDAQ:AIMTKura OncologyNASDAQ:KURAIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 27,123 shares on 7/26/2024Ownership: 0.331%Allspring Global Investments Holdings LLCBought 53,322 shares on 7/26/2024Ownership: 0.066%EFG Asset Management North America Corp.Bought 163 shares on 7/26/2024Ownership: 0.033%Legato Capital Management LLCBought 9,923 shares on 7/26/2024Ownership: 0.023%Summit Securities Group LLCBought 816 shares on 7/26/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions ITCI Stock Analysis - Frequently Asked Questions How have ITCI shares performed this year? Intra-Cellular Therapies' stock was trading at $71.62 on January 1st, 2024. Since then, ITCI stock has increased by 12.2% and is now trading at $80.39. View the best growth stocks for 2024 here. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies's quarterly revenue was up 52.0% on a year-over-year basis. Who are Intra-Cellular Therapies' major shareholders? Top institutional investors of Intra-Cellular Therapies include Bank of New York Mellon Corp (0.33%), Assenagon Asset Management S.A. (0.32%), Raymond James & Associates (0.15%) and DNB Asset Management AS (0.08%). Insiders that own company stock include Sharon Mates, Rory B Riggs, Joel S Marcus, Mark Neumann, Michael Halstead, Suresh K Durgam, Nostrand Robert L Van and Lawrence J Hineline. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV) and Novavax (NVAX). This page (NASDAQ:ITCI) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.